Status:
COMPLETED
Peroral Levosimendan in Chronic Heart Failure
Lead Sponsor:
Orion Corporation, Orion Pharma
Conditions:
Chronic Heart Failure
Heart Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study will investigate the efficacy of oral levosimendan in patients with chronic New York Heart Association (NYHA) IIIb-IV heart failure (HF) using a composite end-point evaluating patient sympto...
Detailed Description
The patients are randomised to 3 groups; higher or lower levosimendan dose group or placebo.
Eligibility Criteria
Inclusion
- Diagnosed chronic heart failure
- Severe symptoms (NYHA IIIb-IV)
- Optimal on-going oral treatment for HF
- Left ventricular ejection fraction less than or equal to 30%
Exclusion
- Severe obstruction of ventricular outflow tracts
- Acute myocardial infarction within 30 days before screening
- Cardiac surgery or coronary angioplasty within 30 days before screening
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00130884
Start Date
March 1 2005
End Date
March 1 2006
Last Update
February 21 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Central Hospital
Helsinki, Finland, 00029